Amplifying Impact Report 2022-23
Message from the Scientific Director, Dr. Fei-Fei Liu
![](../images/icr_sd_fei-fei_liu_500.jpg)
I am delighted to share the Institute of Cancer Research (ICR)'s Amplifying Impact Report 2022-23. Rooted in the theme of ICR's Research Priority Plan 2024-2029 'Amplifying Impact', this report reflects the Institute's milestones, initiatives, and accomplishments since I commenced my term as Scientific Director on September 1, 2022 until the end of calendar 2023.
It has been an incredibly rewarding and active year at the Institute. In 2022-23, ICR embarked on its research priority setting process, which enabled us to learn from the cancer research community and people with lived/living experience, and strategically align our priorities and investments with their needs. We also had the opportunity to engage with other important collaborators such as our fellow CIHR Institutes, and valued national and international funding partners to co-create research opportunities. I am excited to share future announcements with you as ICR begins to implement more initiatives that align with our new research priority areas.
The theme 'Amplifying Impact' has great significance at the Institute. While impact is the ultimate goal for cancer research, of equal value is forging connections, engaging the community, being an active listener and gathering diverse perspectives. These principles are key to generating impactful research and are deeply reflected within all the initiatives and activities presented in our Impact Report.
It is an honour and privilege to serve as ICR's fourth Scientific Director. I would like to thank each member of our community―from our researchers to persons with lived and living experience to our funding partners to community and Indigenous representatives―for your thoughtful engagement with the Institute. I look forward to accomplishing more with you and continuing to 'amplify impact' on the cancer research landscape, improving health for all Canadians.
Respectfully,
Fei-Fei Liu, MD, FRCPC, FASTRO, FCAHS
Scientific Director, Institute of Cancer Research
- Date modified: